Edinburgh researchers say no more than half the drop in heart disease traced back to known risk factors, and suggest treating semaglutide as a heart drug too.
Recap by typeshit. Full story at Healio.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A study of nearly 10,000 matched pairs presented at AAO found no shift in anti-VEGF injections. Other AAO studies looked at AMD and optic neuropathy risk.
A Medscape opinion roundup on food cravings, the long-term staying power of bariatric surgery, and how tirzepatide is starting to compete with it.
Loading…